BR112021020520A2 - Inibidores da di-hidro-orotato desidrogenase - Google Patents

Inibidores da di-hidro-orotato desidrogenase

Info

Publication number
BR112021020520A2
BR112021020520A2 BR112021020520A BR112021020520A BR112021020520A2 BR 112021020520 A2 BR112021020520 A2 BR 112021020520A2 BR 112021020520 A BR112021020520 A BR 112021020520A BR 112021020520 A BR112021020520 A BR 112021020520A BR 112021020520 A2 BR112021020520 A2 BR 112021020520A2
Authority
BR
Brazil
Prior art keywords
dehydrogenase inhibitors
dihydroorotate dehydrogenase
compounds
dihydroorotate
inhibitors
Prior art date
Application number
BR112021020520A
Other languages
English (en)
Inventor
Aihua Wang
Lindsey Deratt
Scott Kuduk
Zhuming Zhang
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112021020520A2 publication Critical patent/BR112021020520A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

inibidores da di-hidro-orotato. desidrogenasea presente invenção refere-se a compostos, composições e métodos para o tratamento de doenças, distúrbios ou condições médicas que são afetados pela modulação de dhodh. esses compostos são representados pela fórmula i a seguir: em que r1, r2, r3, r4, x, e y são definidos neste documento.
BR112021020520A 2019-04-17 2020-04-16 Inibidores da di-hidro-orotato desidrogenase BR112021020520A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835113P 2019-04-17 2019-04-17
PCT/IB2020/053601 WO2020212897A1 (en) 2019-04-17 2020-04-16 Dihydroorotate dehydrogenase inhibitors

Publications (1)

Publication Number Publication Date
BR112021020520A2 true BR112021020520A2 (pt) 2021-12-07

Family

ID=70465152

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020520A BR112021020520A2 (pt) 2019-04-17 2020-04-16 Inibidores da di-hidro-orotato desidrogenase

Country Status (22)

Country Link
US (2) US11505536B2 (pt)
EP (1) EP3956320B1 (pt)
JP (1) JP7566776B2 (pt)
KR (1) KR20220002964A (pt)
CN (1) CN114174278B (pt)
AR (1) AR118724A1 (pt)
AU (1) AU2020259384A1 (pt)
BR (1) BR112021020520A2 (pt)
CA (1) CA3136791A1 (pt)
CL (1) CL2021002681A1 (pt)
CO (1) CO2021015264A2 (pt)
CR (1) CR20210520A (pt)
EC (1) ECSP21081726A (pt)
ES (1) ES2968809T3 (pt)
IL (1) IL287268A (pt)
MA (1) MA55716A (pt)
MX (1) MX2021012706A (pt)
PE (1) PE20220761A1 (pt)
SG (1) SG11202111179RA (pt)
TW (1) TW202104207A (pt)
UY (1) UY38670A (pt)
WO (1) WO2020212897A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230271943A1 (en) * 2020-07-14 2023-08-31 Nanjing Zenshine Pharmaceuticals Co., Ltd. Compounds as dhodh inhibitors
WO2022070068A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2022074534A1 (en) * 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
EP4313150A1 (en) 2021-03-26 2024-02-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Pyrimidine biosynthesis inhibitor combination for use in treating viral infections
IL308333A (en) 2021-05-11 2024-01-01 Janssen Pharmaceutica Nv Combined treatments
CA3215313A1 (en) 2021-05-11 2022-11-17 Nikki DASKALAKIS Combination therapies
IL312078A (en) * 2021-10-13 2024-06-01 Remix Therapeutics Inc Compounds and Methods for Modulating Nucleic Acid Splicing
EP4429663A1 (en) * 2021-11-09 2024-09-18 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists
WO2024114666A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
WO2024114664A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085214A1 (ja) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd ジアリール置換複素５員環誘導体
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
MX2009007831A (es) 2007-01-22 2010-01-15 Gtx Inc Agentes de union de receptor nuclear.
ES2930305T3 (es) * 2013-10-18 2022-12-09 Celgene Quanticel Res Inc Inhibidores del bromodominio
EP4257131A3 (en) * 2014-09-19 2024-01-10 Forma Therapeutics, Inc. Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
AU2015365580B2 (en) 2014-12-18 2020-04-02 Takeda Pharmaceutical Company Limited Solid state forms of fused heteroaromatic pyrrolidinones
WO2018077944A2 (en) 2016-10-27 2018-05-03 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
MA47593A (fr) 2017-02-24 2020-01-01 Merck Patent Gmbh Dérivés de 1, 4, 6-trisubstitué-2-alkyl-1h-benzo[d]imidazole en tant qu'inhibiteurs de dihydroorotate oxygénase
EP3773523A4 (en) 2018-03-26 2021-12-29 Clear Creek Bio, Inc. Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite
TW202043208A (zh) 2019-01-11 2020-12-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
CA3128852A1 (en) * 2019-02-07 2020-08-13 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors

Also Published As

Publication number Publication date
CO2021015264A2 (es) 2021-11-19
UY38670A (es) 2020-10-30
AR118724A1 (es) 2021-10-27
US20200331881A1 (en) 2020-10-22
JP2022530203A (ja) 2022-06-28
AU2020259384A1 (en) 2021-11-11
CR20210520A (es) 2021-12-20
IL287268A (en) 2021-12-01
CL2021002681A1 (es) 2022-05-27
US11505536B2 (en) 2022-11-22
ECSP21081726A (es) 2021-12-30
SG11202111179RA (en) 2021-11-29
CA3136791A1 (en) 2020-10-22
CN114174278A (zh) 2022-03-11
US11753393B2 (en) 2023-09-12
CN114174278B (zh) 2024-08-23
TW202104207A (zh) 2021-02-01
MA55716A (fr) 2022-02-23
EP3956320A1 (en) 2022-02-23
JP7566776B2 (ja) 2024-10-15
MX2021012706A (es) 2022-01-31
WO2020212897A1 (en) 2020-10-22
PE20220761A1 (es) 2022-05-16
EP3956320B1 (en) 2023-11-29
ES2968809T3 (es) 2024-05-14
KR20220002964A (ko) 2022-01-07
US20220298137A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
BR112021020520A2 (pt) Inibidores da di-hidro-orotato desidrogenase
MX2021008400A (es) Inhibidores de dihidroorotato deshidrogenasa.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
CY1121357T1 (el) Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
BR112020008817B8 (pt) Compostos moduladores da via de estresse integrada
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
BR112017006713A2 (pt) inibidor de egfr, e preparação e aplicação do mesmo
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
EA201000750A1 (ru) Производные 4-бензиламино-1-карбоксиацилпиперидина, как ингибиторы бпхэ (белка-переносчика холестериловогоэфира), применимые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
EA201000884A1 (ru) Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
PH12020552206A1 (en) Pyrazole derivatives as malt1 inhibitors
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
BR112022015110A2 (pt) Compostos e usos dos mesmos
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
EA202091804A1 (ru) Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
BR112015011974A2 (pt) derivados de azaquinazolina carboxamida
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112022003405A2 (pt) Inibidores de di-hidro-oratato desidrogenase de ureia substituídas
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
BR112022015109A2 (pt) Compostos e usos dos mesmos
BR112022015351A2 (pt) Compostos heterocíclicos como inibidores de di-hidro-orotato desidrogenase

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]